Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Operation Warp Speed" Does anyone know the "14"? Any educated guesses?
May 1, 2020, 7:41 PM CDT
By Carol E. Lee, Kristen Welker and Elyse Perlmutter-Gumbiner
WASHINGTON — There are 14 potential coronavirus vaccines under development as part of President Donald Trump's administration's program to fast-track one for use as early as January, senior administration officials tell NBC News.
That number was whittled down several weeks ago from 93 vaccines in development that were studied as part of the program, known as “Operation Warp Speed,” officials said.
Over the next two weeks, the 14 remaining vaccines will undergo additional testing and officials expect that anywhere from six to eight of them will make it to a subsequent round of clinical trials. Ultimately, the officials said, the goal is to have three or four vaccines make it through final testing and cleared for use early next year.
https://www.nbcnews.com/politics/white-house/health-officials-eyeing-least-one-14-potential-coronavirus-vaccines-fast-n1198326
"In early January, CEPI approached Kim with a proposition. “They wanted to see if we would be interested in developing a vaccine against this new coronavirus,” Kim says. “And of course we said yes.”
https://cen.acs.org/pharmaceuticals/vaccines/coronavirus-help-mRNA-DNA-vaccines/98/i14
INO 10.28 - how convenient for Citron to omit the White House Meeting including INO's Dr. Kim which should have been at the top of their DD priority list?
https://citronresearch.com/wp-content/uploads/2020/04/Inovio-Pharmaceuticals-Bad-Blood.pdf
Of all the 100% scams out there playing on this covid-bandwagon, Citron bash-shorts INO? Lost a large bit of respect for Citron...
https://www.whitehouse.gov/briefings-statements/remarks-president-trump-members-coronavirus-task-force-meeting-pharmaceutical-companies/
DR. KIM: Mr. President, Mr. Vice President, my name is Joseph Kim. I run a company called Inovio Pharmaceuticals out of Pennsylvania. We’re a proud American biotech company with R&D and manufacturing in California as well.
Inovio is the leader in coronavirus vaccine development in the world. We have a phase two product for related MERS coronavirus vaccine in phase two stage. When the new outbreak occurred, we applied our very innovative 21st century platform called DNA medicines platform to COVID-19. By getting just the DNA sequence of the virus, we were able to fully construct our vaccine within three hours. And we’ve been working on preclinical and preparation work with the help of the FDA in acceleration and really working very well together.
Our plan is to start the U.S.-based clinical trials for COVID-19 vaccine in April of this year; followed by, shortly thereafter, a trial in China, in South Korea. There are a lot more infections in those areas.
THE PRESIDENT: We can give you an area, too.
DR. KIM: (Laughs.)
THE PRESIDENT: No, we can. I mean, you take — you take a look at Seattle again.
DR. KIM: Absolutely.
THE PRESIDENT: We can give you an area.
DR. KIM: Absolutely.
THE PRESIDENT: If you don’t mind.
DR. KIM: We’ve been collaborating with U.S. agencies like DARPA, NIH. We’ve collaborated with Dr. Birx in HIV vaccines many, many years ago. With existing resources and capacity, by end of this year, Inovio could deliver about one million doses, but to scale — by end of this year — but to scale beyond that, we need your help, Mr. President. We need to work with you and your agencies, BARDA, and others to help us scale our vaccine to manufacture in America, to protect American public, also to lead the world in the vaccine development from America. Thank you very much.
THE PRESIDENT: No, thank you very much. You’ll have our help. Thank you.
Swing-trading INO and immediately writing high premium weekly calls...
INO - and how convenient for Citron to omit the White House Meeting including INO's Dr. Kim which should have been at the top of their DD priority list?
https://citronresearch.com/wp-content/uploads/2020/04/Inovio-Pharmaceuticals-Bad-Blood.pdf
Of all the 100% scams out there playing on this covid-bandwagon, Citron bash-shorts INO? Lost a large bit of respect for Citron...
INO - absolutely high-risk but hard to believe that INO's Dr. Kim has snowed every government agency and bigpharma company that was present at the White House Meeting on 3/2/20?
https://www.whitehouse.gov/briefings-statements/remarks-president-trump-members-coronavirus-task-force-meeting-pharmaceutical-companies/
DR. KIM: Mr. President, Mr. Vice President, my name is Joseph Kim. I run a company called Inovio Pharmaceuticals out of Pennsylvania. We’re a proud American biotech company with R&D and manufacturing in California as well.
Inovio is the leader in coronavirus vaccine development in the world. We have a phase two product for related MERS coronavirus vaccine in phase two stage. When the new outbreak occurred, we applied our very innovative 21st century platform called DNA medicines platform to COVID-19. By getting just the DNA sequence of the virus, we were able to fully construct our vaccine within three hours. And we’ve been working on preclinical and preparation work with the help of the FDA in acceleration and really working very well together.
Our plan is to start the U.S.-based clinical trials for COVID-19 vaccine in April of this year; followed by, shortly thereafter, a trial in China, in South Korea. There are a lot more infections in those areas.
THE PRESIDENT: We can give you an area, too.
DR. KIM: (Laughs.)
THE PRESIDENT: No, we can. I mean, you take — you take a look at Seattle again.
DR. KIM: Absolutely.
THE PRESIDENT: We can give you an area.
DR. KIM: Absolutely.
THE PRESIDENT: If you don’t mind.
DR. KIM: We’ve been collaborating with U.S. agencies like DARPA, NIH. We’ve collaborated with Dr. Birx in HIV vaccines many, many years ago. With existing resources and capacity, by end of this year, Inovio could deliver about one million doses, but to scale — by end of this year — but to scale beyond that, we need your help, Mr. President. We need to work with you and your agencies, BARDA, and others to help us scale our vaccine to manufacture in America, to protect American public, also to lead the world in the vaccine development from America. Thank you very much.
THE PRESIDENT: No, thank you very much. You’ll have our help. Thank you.
INO 9.95 - reentered here and wrote the $10-May-8 at $1.15. That's well over 10% for a week. WOW the herd loves to gamble...
I wish the otcmarket website would at least list an O/S count...hard to be interested in a stock with no info. Thanks
ASCLF .374 - I'm interested in this stock that is working on a covid antiviral but I can't find any info whatsoever? Anyone able to dd this one?
The biotech space and with some relation to coronavirus is the ONLY space I have any real interest in buying now.
The leftover froth of this previous 10-year drunkfest of buying is strong. I see a smorgasboard of short-oppurtunities like BYD, COLM, WWE, on & on that should be available for at least 3 more months...
JD 43.50 - are you suggesting a $45 stock might be a leftover china scam? Any more details?
I sold LUVU a few days ago for flat. I had a note to exit before earnings. I think sales of their 'luxury' items will really hurt in the upcoming Q(s) and their masks are way too expensive to ever sell many?
jmo & good luck with it
BYD 18.21 - The Company reported first-quarter 2020 revenues of $680.5 million, down from $827.3 million in the first quarter of 2019. Total Adjusted EBITDAR(1) was $144.4 million in the first quarter of 2020, compared to $223.0 million in the first quarter of 2019. Adjusted Earnings(1) for the first quarter of 2020 reflect a loss of $2.4 million, or $0.02 per share, compared to Adjusted Earnings of $48.9 million, or $0.43 per share, for the same period in 2019.
Operations Review During the period from March 12 through March 18, 2020, the Company was required to close all 29 of its properties nationwide under state and local orders aimed at mitigating the spread of COVID-19. As of April 28, 2020, all Boyd Gaming properties remain closed to the public.
The pps was $16.78 when these numbers were posted. What are the buyers thinking? I've never seen such alice-in-wonderland type buying...moved my 500-share short position into 20 June puts (at reasonable premiums) and ready to put-plunge more on any further buying by, what must be, absolute drunks...
All this in the face of surely horrid earnings for Q2 for 95% of all companies, and no guidance past that. Not to mention, an economy that could take years to get back to normal.
I believe this might be the first time I agree with you 100%. In some 20 years of serious investing, this is the first time I am holding no long positions, none...all cash and a few shorts. This market has "doom" written all over it...
BYD 15.75 - went short on an earnings stinker...Boyd Gaming Swings to Q1 Net Loss, Missing Street View, As Revenue Falls 17.7% After COVID-19 Pandemic Closes Casinos MT NEWSWIRES 3:23 PM ET 4/28/2020
There's actually steady buying in afterhours - UNBELIEVABLE - the exhuberance is strong with this madding-GULLIBLE-herd, like a real bad addiction? What are they thinking,
"Well maybe one day the casinos will open again, ONE DAY MAYBE?"
MNRO 51.15 +5.40 - also shorted this muffler shop. Unreal buying...as loopy as I've ever seen...
shorting individual stocks is the best & most reliable way of winning in a bear market
BFAM posts earnings on 5/6 - should get seriously u-g-l-y and BFAM will be directly in my short sights. Anyone with another opinion?
The Lockdowns Were the Black Swan
How and why we went from ‘flatten the curve’ to choosing between our economy and the virus.
By Holman W. Jenkins, Jr.
April 24, 2020 5:56 pm ET
To some the coronavirus is a supporting actor in a drama titled “The Iniquities of Donald Trump.” Those of more balanced mind wonder whether Mr. Trump’s failings can be distinguished from the predictable and expected failings of the U.S. government.
But it’s unlikely Mr. Trump will seem important to historians telling the story. Columbia University once found that only 20% of flu sufferers and 5% of cold sufferers bothered to see a doctor. This is why the Wuhan virus was destined to go world-wide even if China had been upfront or an American president had been clairvoyant. Every bit of data since has confirmed it. Infectious respiratory diseases are a fact of nature. Beijing was finally driven to action by the same consideration that drove other countries to action—when the number of infected people and the duration of their cases overwhelmed a local hospital system.
This is the proximate crisis that called for a public response around the world. Novel pandemic diseases are not a black swan. Our lockdown response was a black swan.
We started off sensibly. “This is not something [American families] generally need to worry about,” said CDC’s Dr. Nancy Messonnier in mid-January. “It’s a very, very low risk to the United States,” said Dr. Anthony Fauci a week later.
Bill de Blasio, mayor of New York, urged residents to go about their business normally as recently as March 11.
As coldblooded as it seems, these were the right statements at the time. Under “flatten the curve,” changes in public behavior aren’t needed until they are needed. Roll that around in your mind a bit. The better we do at equipping local hospitals, the less we need to bankrupt local businesses and their workers to slow the virus as it runs its course through society. That was the idea we started with.
Not even the U.K. Imperial College study that so alarmed the world’s policy makers recommended indiscriminate lockdowns and shelter-in-place orders. If we meant what we said, we’ve overshot in many places. Beds are empty. A ventilator shortage did not materialize. We failed to set aside enough capacity to treat other medical conditions like strokes and heart attacks. This is costing lives.
What happened? From Bill Gates to your local editorialist, a new priority waddled to the fore. We decided that, whatever contributes to killing Americans at a routine total rate of 8,000 or so a day, it shouldn’t be the coronavirus.
Accidents, yes—6% of deaths. Heart disease, yes—23%. Flu and pneumonia, yes—2%.
These deaths are allowed but not deaths from the coronavirus even at the cost of economic ruin for millions. Of course the media and public are free to decide now they never wanted flatten the curve; they wanted to be spared the virus altogether. But explain how this is to be done. And explain why. The Economist magazine says we can’t restart the economy without an “unprecedented” $180 billion testing regime. Unprecedented is an interesting word because China, a country of 1.4 billion people with eight cities larger than New York, either must have developed such a system with nobody noticing or hasn’t found it necessary.
With its porous southern border, with its nine million overseas citizens who can come home whenever they want, the U.S. isn’t New Zealand. Even so, I wonder if New Zealand a year from now will think it was sensible to seal itself off from the world to avoid a disease that may not be more deadly for the average person than the flu and certainly will not be extinguished elsewhere.
U.S. politicians, sensitive to their survival in office, are stuck trying to save their constituents simultaneously from the virus and poverty, and get only cheap shots from the media. Restarting the economy will lead to more coronavirus deaths—and more motor-vehicle deaths, more workplace deaths, even flu deaths.
What Americans need now is not another celebrity ad repeating the unsustainable “stay at home” mantra. They need detailed advice from government about how transmission does and does not occur (do masks help? are surface residues a significant threat? does infection confer immunity?) so they can learn to live with a virus that isn’t going away at least until a vaccine is developed.
And, for God’s sake, the media should stop confusing “infection fatality rate” with “case fatality rate,” grotesquely misleading the public on the true death rate. It’s hard to see why anybody would even report case fatality rate, a number without meaning since most of those tested either had celebrity access to testing or symptoms severe enough to require hospitalization (i.e., the equivalent of counting drunks and people who drive blue Austin-Healeys to estimate the risk of dying in a car accident).
Notice I have not mentioned Donald Trump since the second paragraph, because he has yet to find a way to be particularly relevant to this story—which I know will be shocking to readers who think the failings of Mr. Trump dwarf all other narratives.
https://www.wsj.com/articles/the-lockdowns-were-the-black-swan-11587765416?mod=opinion_featst_pos1
The Lockdowns Were the Black Swan
How and why we went from ‘flatten the curve’ to choosing between our economy and the virus.
By Holman W. Jenkins, Jr.
April 24, 2020 5:56 pm ET
To some the coronavirus is a supporting actor in a drama titled “The Iniquities of Donald Trump.” Those of more balanced mind wonder whether Mr. Trump’s failings can be distinguished from the predictable and expected failings of the U.S. government.
But it’s unlikely Mr. Trump will seem important to historians telling the story. Columbia University once found that only 20% of flu sufferers and 5% of cold sufferers bothered to see a doctor. This is why the Wuhan virus was destined to go world-wide even if China had been upfront or an American president had been clairvoyant. Every bit of data since has confirmed it. Infectious respiratory diseases are a fact of nature. Beijing was finally driven to action by the same consideration that drove other countries to action—when the number of infected people and the duration of their cases overwhelmed a local hospital system.
This is the proximate crisis that called for a public response around the world. Novel pandemic diseases are not a black swan. Our lockdown response was a black swan.
We started off sensibly. “This is not something [American families] generally need to worry about,” said CDC’s Dr. Nancy Messonnier in mid-January. “It’s a very, very low risk to the United States,” said Dr. Anthony Fauci a week later.
Bill de Blasio, mayor of New York, urged residents to go about their business normally as recently as March 11.
As coldblooded as it seems, these were the right statements at the time. Under “flatten the curve,” changes in public behavior aren’t needed until they are needed. Roll that around in your mind a bit. The better we do at equipping local hospitals, the less we need to bankrupt local businesses and their workers to slow the virus as it runs its course through society. That was the idea we started with.
Not even the U.K. Imperial College study that so alarmed the world’s policy makers recommended indiscriminate lockdowns and shelter-in-place orders. If we meant what we said, we’ve overshot in many places. Beds are empty. A ventilator shortage did not materialize. We failed to set aside enough capacity to treat other medical conditions like strokes and heart attacks. This is costing lives.
What happened? From Bill Gates to your local editorialist, a new priority waddled to the fore. We decided that, whatever contributes to killing Americans at a routine total rate of 8,000 or so a day, it shouldn’t be the coronavirus.
Accidents, yes—6% of deaths. Heart disease, yes—23%. Flu and pneumonia, yes—2%.
These deaths are allowed but not deaths from the coronavirus even at the cost of economic ruin for millions. Of course the media and public are free to decide now they never wanted flatten the curve; they wanted to be spared the virus altogether. But explain how this is to be done. And explain why. The Economist magazine says we can’t restart the economy without an “unprecedented” $180 billion testing regime. Unprecedented is an interesting word because China, a country of 1.4 billion people with eight cities larger than New York, either must have developed such a system with nobody noticing or hasn’t found it necessary.
With its porous southern border, with its nine million overseas citizens who can come home whenever they want, the U.S. isn’t New Zealand. Even so, I wonder if New Zealand a year from now will think it was sensible to seal itself off from the world to avoid a disease that may not be more deadly for the average person than the flu and certainly will not be extinguished elsewhere.
U.S. politicians, sensitive to their survival in office, are stuck trying to save their constituents simultaneously from the virus and poverty, and get only cheap shots from the media. Restarting the economy will lead to more coronavirus deaths—and more motor-vehicle deaths, more workplace deaths, even flu deaths.
What Americans need now is not another celebrity ad repeating the unsustainable “stay at home” mantra. They need detailed advice from government about how transmission does and does not occur (do masks help? are surface residues a significant threat? does infection confer immunity?) so they can learn to live with a virus that isn’t going away at least until a vaccine is developed.
And, for God’s sake, the media should stop confusing “infection fatality rate” with “case fatality rate,” grotesquely misleading the public on the true death rate. It’s hard to see why anybody would even report case fatality rate, a number without meaning since most of those tested either had celebrity access to testing or symptoms severe enough to require hospitalization (i.e., the equivalent of counting drunks and people who drive blue Austin-Healeys to estimate the risk of dying in a car accident).
Notice I have not mentioned Donald Trump since the second paragraph, because he has yet to find a way to be particularly relevant to this story—which I know will be shocking to readers who think the failings of Mr. Trump dwarf all other narratives.
https://www.wsj.com/articles/the-lockdowns-were-the-black-swan-11587765416?mod=opinion_featst_pos1
IPATF .57 - IPA Awarded Grant Focused on Coronavirus and Other Emerging Pathogens
FARGO, ND , April 24, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), is pleased to announce that the state of North Dakota has awarded a Bioscience Innovation Grant totalling US$75,000 for the enhancement of a novel platform for rapidly developing treatments for COVID-19 and other emerging pathogens.
"Advances in bioscience have already transformed many sectors including agriculture and medicine," state Agriculture Commissioner Doug Goehring said. "These grants will help North Dakota stay on the forefront of bioscience innovation."
The Company reports that this grant was the first application of many to be submitted by IPA over the next several months.
"ImmunoPrecise is in the process of applying for both state and federal grants to support the development of a treatment for COVID-19 using our PolyTopeTM mAb Therapy," stated Jennifer Bath , IPA President and CEO. "We turned first to the State of North Dakota , given their strong history of support for Biotechnology and Innovation. It is with gratitude we accept the ND Bioscience Innovation Grant and we are confident we can leverage this funding, along with our research advances, to continue to build on our current successes."
Furthermore, the company is also pleased to announce that that it has been approved for a US$209,000 loan under the Payroll Protection Program ("PPP") administered by the U.S. Small Business Administration.
https://finance.yahoo.com/news/immunoprecise-updates-state-federal-funding-172600570.html
IPATF .57 - IPA Awarded Grant Focused on Coronavirus and Other Emerging Pathogens
FARGO, ND , April 24, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), is pleased to announce that the state of North Dakota has awarded a Bioscience Innovation Grant totalling US$75,000 for the enhancement of a novel platform for rapidly developing treatments for COVID-19 and other emerging pathogens.
"Advances in bioscience have already transformed many sectors including agriculture and medicine," state Agriculture Commissioner Doug Goehring said. "These grants will help North Dakota stay on the forefront of bioscience innovation."
The Company reports that this grant was the first application of many to be submitted by IPA over the next several months.
"ImmunoPrecise is in the process of applying for both state and federal grants to support the development of a treatment for COVID-19 using our PolyTopeTM mAb Therapy," stated Jennifer Bath , IPA President and CEO. "We turned first to the State of North Dakota , given their strong history of support for Biotechnology and Innovation. It is with gratitude we accept the ND Bioscience Innovation Grant and we are confident we can leverage this funding, along with our research advances, to continue to build on our current successes."
Furthermore, the company is also pleased to announce that that it has been approved for a US$209,000 loan under the Payroll Protection Program ("PPP") administered by the U.S. Small Business Administration.
https://finance.yahoo.com/news/immunoprecise-updates-state-federal-funding-172600570.html
IPATF .57 - IPA Awarded Grant Focused on Coronavirus and Other Emerging Pathogens
FARGO, ND , April 24, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), is pleased to announce that the state of North Dakota has awarded a Bioscience Innovation Grant totalling US$75,000 for the enhancement of a novel platform for rapidly developing treatments for COVID-19 and other emerging pathogens.
"Advances in bioscience have already transformed many sectors including agriculture and medicine," state Agriculture Commissioner Doug Goehring said. "These grants will help North Dakota stay on the forefront of bioscience innovation."
The Company reports that this grant was the first application of many to be submitted by IPA over the next several months.
"ImmunoPrecise is in the process of applying for both state and federal grants to support the development of a treatment for COVID-19 using our PolyTopeTM mAb Therapy," stated Jennifer Bath , IPA President and CEO. "We turned first to the State of North Dakota , given their strong history of support for Biotechnology and Innovation. It is with gratitude we accept the ND Bioscience Innovation Grant and we are confident we can leverage this funding, along with our research advances, to continue to build on our current successes."
Furthermore, the company is also pleased to announce that that it has been approved for a US$209,000 loan under the Payroll Protection Program ("PPP") administered by the U.S. Small Business Administration.
https://finance.yahoo.com/news/immunoprecise-updates-state-federal-funding-172600570.html
GNTX 23 - went short on the numbers...Gentex Q1 Earnings, Sales Slide Amid COVID-19 Pandemic; Slashes FY20 Sales Guidance
MT NEWSWIRES 7:45 AM ET 4/24/2020
WWE 45 (up 13% afterhours) - added shorts...like so many other companies, WWE reported strong Q1 numbers and NO CLUE as to the future...and the irrational exhuberant madding-herd just can't seem to snap out of it's drunken stupor?
WWE stock price target raised to $50 from $46 at Benchmark
MARKETWATCH 5:21 AM ET 4/24/2020
WOW
PEN 185 - what's your short take? From their recent "covid" update...
Update on First Quarter and Full Year 2020 Outlook
Revenue for the first quarter of 2020 is expected to be in the range of $137.0 to $137.3 million.
In the quarter, the Company began to observe more notable negative impact on business trends in March due to COVID-19. Due to the rapidly evolving environment and continued uncertainties resulting from COVID-19, the Company is withdrawing its previously announced annual revenue guidance for 2020. Although the Company cannot currently predict the specific extent or duration of the impact of the COVID-19 outbreak on its financial and operating results, the Company does expect the impact of COVID-19 could be more significant in the short term.
Penumbra continues to have a strong cash position and no debt. In light of the current situation, the Company is actively reviewing and implementing cost saving measures. In addition, more than twenty senior executives have voluntarily taken substantial temporary salary reductions. These measures are being undertaken to navigate the current environment, and to allow the Company to be in a strong financial and operating position after the outbreak.
The Company plans to provide final results, commentary and additional information related to the impact of COVID-19 on its upcoming Q1 2020 earnings call, which is expected to be in early May.
https://finance.yahoo.com/news/penumbra-provides-covid-19-response-200500519.html
I own some puts and swingtrading a few shorts...
INO($12.55), up 300% 1 month- a good short?
Problem I see shorting the vaccine/cure stocks is the Fed is likely to fund them huge at any minute.
https://finance.yahoo.com/news/moderna-snares-483-million-u-223631295.html
Otherwise, they should be great trading stocks (both sides) for months to come...
What's your take on SUI? Good short candidate or would you pass or even buy? Looks like a prime short&hold to me?
I don't understand REIT's either, broad-markets even less. At least a REIT offers some exact fundamentals - trying to figure market directions is better left to clairvoyants imo.
You didn't like SUI at $120.00? They just posted a (.17) loss and pulled all future guidance!
O'Reilly Automotive (ORLY) PT Raised to $380 at Wedbush
https://www.streetinsider.com/Analyst+PT+Change/OReilly+Automotive+%28ORLY%29+PT+Raised+to+%24380+at+Wedbush/16775301.html
I wonder what part of the earnings report did this analyst read, if any part at all?
PFE 36.25 - is like #4 in the race to vaccine and the pps is far from up 200% - PFE pps remains in the forever-in-infamy March/2020 chart rut! INO, NVAX, and MRNA all exploding, each with a gazillion warts, while PFE qualifies an actual VALUE-buy on it's own.
https://finance.yahoo.com/news/pfizer-rises-nod-start-first-152552308.html
wade, buying/selling stocks - what has changed exactly? In the grand scheme of things, NOTHING, still about finding stocks underpriced or overpriced and timing one's buys and sells correctly...
ATGN - it looks ok. I would be interested in another space & time but right now if a stock is not DIRECTLY tied to the covid-hysteria (vaccines, cures, masks) then the stock is a likely short candidate imo
also shorted a few SUI and XLNX and am tempted to short some of wade's choice, LRCX, but why when there is such a smorgasboard of absolute flyingpigs out there with very slim chance to see any daylight on the horizon...
ORLY 386 - shorted a few in afterhours after what I considered a horrible near-term outlook (go figure) but the madding-crowd seems to adore the numbers?
NBIO .135 - posted February 27, 2020...The only company with a target for vimentim is Nascent Biotech Inc. (OTCMKT: NBIO). Their lead candidate is pritumumab which was a phase 2 brain cancer asset in Japan. They have redone their cell line for study and on the cusp of starting their phase 1 cancer trial.
https://insiderfinancial.com/top-coronavirus-stocks-backed-by-scientific-evidence/179657/
posted April 22, 2020...The Company has initiated tests to assess the possibility that its lead asset, the monoclonal antibody Pritumumab (PTB) could be used as a potential therapy against the novel coronavirus, or SARS-CoV-2, which has caused a global pandemic (COVID-19). As specifically mentioned in a 2016 article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7), cell-surface vimentin (recognized by PTB), is implicated in the entry of SARS-CoV-2, into the cells it infects. The Company has engaged independent third party consultants to conduct the tests and initial results are forthcoming.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Provides-Shareholder-Update-on-COVID-19-Therapy-and-Brain-Cancer-Trials?id=259797
Anyone with an opinion on "Pritumumab"? NBIO's market-cap is less than $6M...
NBIO .135 - posted February 27, 2020...The only company with a target for vimentim is Nascent Biotech Inc. (OTCMKT: NBIO). Their lead candidate is pritumumab which was a phase 2 brain cancer asset in Japan. They have redone their cell line for study and on the cusp of starting their phase 1 cancer trial.
https://insiderfinancial.com/top-coronavirus-stocks-backed-by-scientific-evidence/179657/
posted April 22, 2020...The Company has initiated tests to assess the possibility that its lead asset, the monoclonal antibody Pritumumab (PTB) could be used as a potential therapy against the novel coronavirus, or SARS-CoV-2, which has caused a global pandemic (COVID-19). As specifically mentioned in a 2016 article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7), cell-surface vimentin (recognized by PTB), is implicated in the entry of SARS-CoV-2, into the cells it infects. The Company has engaged independent third party consultants to conduct the tests and initial results are forthcoming.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Provides-Shareholder-Update-on-COVID-19-Therapy-and-Brain-Cancer-Trials?id=259797
Anyone with an opinion on "Pritumumab"? NBIO's market-cap is less than $6M...
The Company has initiated tests to assess the possibility that its lead asset, the monoclonal antibody Pritumumab (PTB) could be used as a potential therapy against the novel coronavirus, or SARS-CoV-2, which has caused a global pandemic (COVID-19). As specifically mentioned in a 2016 article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7), cell-surface vimentin (recognized by PTB), is implicated in the entry of SARS-CoV-2, into the cells it infects. The Company has engaged independent third party consultants to conduct the tests and initial results are forthcoming.
Trading at $6M cap, the risk/reward here appears to be off the charts...
What are some of this board's favorite gold stocks? Definitely time to at least get interested in them?
Just returned from Chase Bank - I withdrew $2k cash and requested all 100 dollar bills. BRAND NEW crisp and even had that strong distinctive newness smell...funny munny
VXRT 3.25 - nice call. Do you have a good link to the "Janssen" connection?
WWE 40.57 - bought puts into Q1 earnings scheduled for 4/23 afterclose. How does an all but hopeless stock like this continue sporting a 40+ P/E?
There's no going back to normal EVER after this mandate of "F off sixfeet or more you disease carrying loser". In the slim chance they ever do fill a stadium or arena ever again, any sneeze will bring a punch in the face. Just imagine sneezing in a wrestling arena...